Research for novel compounds that may block bacterial development has continued and prompted by antibiotic-resistant bacteria. The expenses of community for health care as a result of antibiotic resistance has indeed been remarkable during the last decades and demand immediate of medical attention. Consequently, this research presents the antibacterial effect of genuine metal oxide nanoparticles against Escherichia coli (E. coli) and Klebsiella pneumoniae that have been isolated from urinary tract infection patients. This is because metal oxide nanomaterials have already been utilised a compromise with some of its comprehensive implementations throughout the pharmaceutical and biological disciplines of nano-biotechnology. The biological activity of zirconium oxide (ZrO₂) nanoparticles against bacteria is investigated using agar well diffusion approach. The antibacterial efficiency of nanoparticles on E. coli and Klebsiella pneumoniae using both qualitative and quantitative assessment approaches is appraised. Specifically, an aseptic technique is used to collect fifty urine samples into sterile tubes. To inoculate the patients' midstream urine on both blood agar and MacConkey agar plates, the direct streaking approach is employed. Scanning electron microscopy (SEM) and X–Ray diffraction (XRD) techniques are used to signify the physical features nanoparticle including shape and size. The identified cubic components of SEM and XRD techniques indicate the existence of ZrO₂ nanoparticles and magnetic nanoparticles of particle size ranges between 5 to 50 nm. According to the data, ZrO₂ nanoparticles have a bacteriostatic effect at 0.1 mg/ml with an absorption of 0.2 and a bactericidal effect at 2 mg/ml with an absorption of 0.007 on E. col isolates. Additionally, ZrO₂ nanoparticles exhibit bacteriostatic (at 0.1 mg/ml with absorption of 0.3) and bactericidal (at 2 mg/ml with absorption of 0.001) effects on Klebsiella pneumoniae isolates. Among all the antibiotics utilised, gentamicin shows the lowest rate of resistance, suggesting that it is more effective against E. coli and Klebsiella pneumoniae when ZrO₂ is presented.

对可能阻止细菌发育的新型化合物的研究仍在继续，并受到抗生素耐药性细菌的推动。在过去的几十年中，由于抗生素耐药性而导致的社区医疗保健费用确实非常高，需要立即就医。因此，本研究展示了真正的金属氧化物纳米颗粒对从尿路感染患者中分离出的大肠杆菌和肺炎克雷伯菌的抗菌作用。这是因为金属氧化物纳米材料已经在纳米生物技术的制药和生物学科中得到了一些综合应用的折衷利用。使用琼脂井扩散方法研究了氧化锆（ZrO ₂ ）纳米粒子对细菌的生物活性。使用定性和定量评估方法评估纳米颗粒对大肠杆菌和肺炎克雷伯菌的抗菌效率。具体来说，使用无菌技术将五十个尿液样本收集到无菌管中。为了将患者的中流尿液接种到血琼脂和麦康凯琼脂平板上，采用直接划线方法。扫描电子显微镜 (SEM) 和 X 射线衍射 (XRD) 技术用于表征纳米颗粒的物理特征，包括形状和尺寸。 SEM和XRD技术鉴定的立方成分表明存在粒径范围在5至50 nm之间的ZrO ₂纳米颗粒和磁性纳米颗粒。据数据显示，ZrO ₂纳米颗粒在0.1mg/ml时对大肠杆菌分离株具有抑菌作用，吸光度为0.2；在2mg/ml时具有杀菌作用，吸光度为0.007。此外，ZrO _{2纳米粒子对}肺炎克雷伯菌分离株表现出抑菌（0.1 mg/ml，吸收率为0.3）和杀菌（2 mg/ml，吸收率为0.001）作用。在所有使用的抗生素中，庆大霉素的耐药率最低，这表明当ZrO ₂存在时，庆大霉素对大肠杆菌和肺炎克雷伯菌更有效。